White crystalline solid. HYGROSCOPIC. A reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of G_a-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca²⁺-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-b. An inhibitor of phospholipase D (IC₅₀ = 15 µM). Reported to interact with ATP-binding enzymes and P₂-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids. Purity: ≥98% by HPLC. RTECS QM7000000, CAS 129-46-4.

Merck Index: 14, 9006
Ref.: Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130. Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346. Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808. Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281. Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443. Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717. Denhertog, A., et al. 1992. J. Physiol. 454, 591. Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661. Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73. Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304. Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.